Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

"Women come significantly later to their cardiologists and have the same peri-procedural [alcohol septal ablation] complications and worse long-term outcomes, which are caused by their older age; ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Mavacamten, an investigational allosteric modulator of cardiac myosin, has proved superior to placebo for improving symptoms and reducing or eliminating obstruction of the left ventricle in patients ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first ...

Hypertrophic cardiomyopathy (HCM) is a primary disease of cardiac muscle characterized by a thickening of the left ventricular wall and often predominantly affecting the interventricular septum. This ...

Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiac condition and the leading cause of sudden cardiac death (SCD) in young adults. Given that SCD can be the first and most ...

Hypertrophic cardiomyopathy (HCM) is often seen in patients as an autosomal dominant genetic heart disease with a variable clinical course. It is characterized by left ventricular hypertrophy, and ...

The physical symptoms of obstructive hypertrophic cardiomyopathy (HCM) are very real, ranging from chest pain and shortness of breath to a racing heart, lightheadedness, and fatigue. But there’s also ...